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Abstract Numerous microarray-based gene expression
studies performed on several types of solid tumors revealed
significant changes in key genes involved in progression
and regulation of the cell cycle, including AURKA that is
known to be overexpressed in many types of human
malignancies. Tumor hypoxia is associated with poor
prognosis in several cancer types, including breast cancer
(BC). Since hypoxia is a condition that influences the
expression of many genes involved in tumorigenesis, pro-
liferation, and cell cycle regulation, we performed a
microarray-based gene expression analysis in order to
identify differentially expressed genes in BC cell lines
exposed to hypoxia. This analysis showed that hypoxia
induces a down-regulation of AURKA expression.
Although hypoxia is a tumor feature, the molecular
mechanisms that regulate AURKA expression in response
to hypoxia in BC are still unknown. For the first time, we
demonstrated that HIF-1 activation downstream of hypoxia
could drive AURKA down-regulation in BC cells. In fact,
we found that siRNA-mediated knockdown of HIF-1a
significantly reduces the AURKA down-regulation in BC
cells under hypoxia. The aim of our study was to obtain
new insights into AURKA transcriptional regulation in
hypoxic conditions. Luciferase reporter assays showed a
reduction of AURKA promoter activity in hypoxia. Unlike
the previous findings, we hypothesize a new possible
mechanism where HIF-1, rather than inducing transcrip-
tional activation, could promote the AURKA down-regu-
lation via its binding to hypoxia-responsive elements into
the proximal region of the AURKA promoter. The present
study shows that hypoxia directly links HIF-1 with AURKA
expression, suggesting a possible pathophysiological role
of this new pathway in BC and confirming HIF-1 as an
important player linking an environmental signal to the
AURKA promoter. Since AURKA down-regulation over-
rides the estrogen-mediated growth and chemoresistance in
BC cells, these findings could be important for the devel-
opment of new possible therapies against BC.
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Introduction
Breast cancer (BC) is one of the most common cancers and
a major cause of death among women worldwide [1].
Advances in molecular characterization of tumor by
microarray profiling allowed the identification of five dis-
tinct molecular subtypes of BC which have led to the
identification of a large number of novel targets and, in
parallel, to the development of multiple approaches for
anticancer therapy [2, 3]. Numerous microarray-based gene
expression studies performed on several types of solid
tumors revealed significant changes in key genes involved
in progression and regulation of the cell cycle [4, 5].
Aberrations in genetic pathways controlling cell cycle
cause abnormal cell growth, senescence, and apoptosis,
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inducing malignant transformation of cells [6, 7]. Aurora
kinases are a novel family of mitotic serine/threonine
kinases involved in different processes of cell cycle control
[8]. Aurora kinase A (AURKA), whose expression is cell
cycle dependent, is mainly involved in centrosome matu-
ration, spindle assembly, and chromosome segregation, and
it is associated with several co-activators such as BORA,
TPX2, Ajuba (JUB), TACC1, and GADD45a that drive the
localization, activation, and substrate preference during
cell division [9, 10]. AURKA is overexpressed in many
types of human malignancies, such as breast, bladder,
ovarian, colorectal, pancreatic, and gastric cancers [11–13].
This overexpression correlates with tumorigenesis, metas-
tasis, and chemoresistance, confirming the pro-survival
function of AURKA in cancer cells. Aurora-A overex-
pression may be achieved not only by gene amplification
but also by other mechanisms such as transcription acti-
vation or suppression of protein degradation. Several
studies, carried out on different tumors, showed that AU-
RKA transcription may be induced by HIF-1a, E2F3,
E4TF1, TRAP220/MED1, and c-Myc [14–16]. However,
the mechanism of transcriptional regulation of AURKA
remains largely unknown, especially in BC.
In recent years, small molecules with an inhibiting
action toward the aurora kinase family were developed.
These molecules can act by blocking the protein–protein
interaction between the aurora kinase and its substrates or
blocking the ATP-binding site of the serine threonine
kinase [17].
A typical feature of the microenvironment of several solid
tumors is the hypoxia [18] that influences the expression of
various proteins involved in proliferation and cell cycle pro-
gression [19–21]. The stabilization of the hypoxia-inducible
transcription factor, HIF-1, is a crucial event that induces
changes in the expression of many genes implicated in the
growth and survival of neoplastic cells [22, 23]. HIF-1 is
made up of two subunits, a and b [24]. Subunit b is consti-
tutively expressed and its activity is oxygen independent. The
expression of the subunit a is induced by cell hypoxia and
kept at low levels in a great many cells in normoxia [25, 26].
Under normoxic conditions, HIF-1a is targeted for degrada-
tion through the hydroxylation of its oxygen-dependent
degradation domain (ODDD) by prolyl hydroxylases (PHDs)
[27]. Von Hippel-Lindau protein (pVHL), which is a com-
ponent of the E3 ubiquitin ligase complex, recognizes prolyl-
hydroxylated HIF-1a and drives its polyubiquitination and
proteasomal degradation. Under hypoxia, HIF-1a subunit is
stabilized and dimerizes with HIF-1b, translocates to the
nucleus, and activates transcription of target genes via bind-
ing to hypoxia-responsive elements (HREs) [22, 28]. HIF-1
induces the expression of more than 100 genes [29], including
the vascular endothelial growth factor (VEGF), glycolytic
enzymes [30], and various genes involved in proliferation and
cell cycle progression, to insure the cancer cell survival [20,
31, 32]. Recently, the HIF-1 role as a repressor in response to
hypoxia has been shown in several tumors. In 2005, Chen
et al. [33] showed that the suppression of the CAD expression
under hypoxia is HIF-1a dependent in human colon cancer
cells, inducing cell proliferation arrest. Furthermore, Feige
et al. [34] reported that HIF-1 represses the expression of the
MITF oncogene through induction of the transcriptional
repressor DEC1 in melanoma and clear cell sarcoma cells. In
addition, in 2011, Ryu et al. [35] described the HIF-1 role as
transcriptional repressor of the estrogen receptor alpha (ERa)
gene in MCF-7 and T47D human BC cells under hypoxia.
The authors showed that hypoxia induces HIF-1a-mediated
repression of the ESR1 gene at the transcriptional level,
promoting hormone insensitivity in the tumor microen-
vironment.
Although hypoxia is a typical tumor condition, the
molecular mechanisms that regulate AURKA expression in
response to hypoxic condition in BC are still unknown.
Therefore, the aim of our study was to obtain new insights on
AURKA regulation in BC cell lines under hypoxia, by evalu-
ating the possible HIF-1 role in transcriptional control of
AURKA expression. In this work, we hypothesize that hypoxia
down-regulates AURKA expression in a HIF-1a-dependent
manner, suggesting, for the first time, a novel potential role of
HIF-1 as transcriptional repressor of AURKA in BC cells.
Methods
Cell culture
Human BC cell lines, MCF-7, MDA-MB-231, and SK-Br3,
purchased from the American Type Culture Collection
(Rockville, MD, USA), were cultured in Dulbecco’s Mod-
ified Eagle Medium (DMEM:F12) supplemented with 10 %
fetal bovine serum (FBS) and antibiotics (100 U/mL peni-
cillin and 50 mg/mL streptomycin) (Invitrogen, Carlsbad,
CA, USA).
Cell lines were cultured at 80 % confluence in a
normoxic atmosphere of 16 % O2, 79 % N2, and 5 % CO2
(by volume) for 24 h. Then, medium was renewed and
cells were further cultured under normoxia or hypoxia
(3 % O2, 87 % N2, 5 % CO2, by volume) at two different
time points, 24 and 48 h.
Microarray analysis
Microarray analysis was performed as previously described
[36]. Total RNA was extracted according to the manufac-
turer’s protocol (Affymetrix, Santa Clara, CA). Fragmented
cRNA was hybridized using a human oligonucleotide array
U133 Plus 2.0 (Genechip Affymetrix, Santa Clara, CA).
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Washing and staining were performed through Affymetrix
GeneChip Fluidic Station 450. Probe arrays were scanned
using Affymetrix GeneChip Scanner3000 G7 enabled for
High-Resolution Scanning. Two biological replicates were
performed for each experimental condition. Images were
extracted with the GeneChip Operating Software (Affyme-
trix GCOS v1.4). Quality control of the arrays was per-
formed using the AffyQCReport software [37].
Statistical analysis
For statistical analysis, the background subtraction and
normalization of probe set intensities were performed using
the method of Robust Multiarray Analysis (RMA) descri-
bed by Irizarry et al. [38]. To identify differentially
expressed genes (DEGs), gene expression intensity was
compared using a moderated t test and a Bayes smoothing
approach developed for a low number of replicates [39]. To
correct for the effect of multiple testing, the false discovery
rate was estimated from P values derived from the mod-
erated t test statistics [40]. The analysis was performed
using the affylmGUI Graphical User Interface for the
Limma Microarray Package (Bioconductor Software) [41].
Significant differences were determined by Student’s
t test. P\0.05 was considered to be statistically significant.
Microarray data analysis
Hierarchical cluster (HCA) and heat map analyses were
performed using the MultiExperiment Viewer (MeV v4.8)
program of TM4 Microarray Software Suite.
The Gene Set Analysis Toolkit was used to investigate
the biological significance of a set of genes represented by
the specific expression pattern during the progression of
cell cycle. DEGs were analyzed according to predefined
pathways annotated by KEGG [42] and Biocarta bioin-
formatic resources. For an over-represented KEGG or
Biocarta pathway, a cutoff P value of 0.01 was selected.
All shown values are in logarithm scale.
Quantitative real-time PCR (qRT-PCR) and RT-PCR
Total cellular RNA was extracted using RNeasy Mini Kit
(Qiagen Inc., Valencia, CA, USA). Then, RNA was con-
trolled through 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA) and quantified through the spectro-
photometer NanoDrop ND-1000 (CELBIO). For AURKB,
AURKA, and HIF-1a mRNA detection, 2 ng of total RNA
was reverse transcribed into single-stranded cDNA using
high capacity cDNA reverse transcription kit (Applied
Biosystems, Foster City, CA, USA) according to the ven-
dor’s instructions. Gene primers for AURKA, AURKB, and
HIF-1a were purchased from Applied Biosystems (TaqMan
gene expression assay). Quantitative real-time PCR (qRT-
PCR) was performed with the ABI PRISM 7900 sequence
detection system (Applied Biosystems, Foster City, CA,
USA) using SDS software version 2.1. The reactions were
performed in triplicate and the results were normalized using
Human b-actin Pre-Developed TaqMan assay reagents
(Applied Biosystems). Changes in the target mRNA content
were determined using a comparative CT method (ABI User
Bulletin No. 2). An average CT value for each RNA was
obtained for triplicate reactions. A reverse transcription
polymerase chain reaction (RT-PCR) was also performed in
order to confirm the results previously obtained with qRT-
PCR. The data were evaluated in 2 % agarose gel.
Western blotting (WB)
Cells were lysed using the complete Lysis-M reagent set
(Roche, Mannheim Germany). Protein concentration was
measured using Quick Start Bradford (Bio-Rad Laborato-
ries, Hercules, CA). 80–100 lg of total protein lysate was
separated on 10 % polyacrylamide gel under denaturing
conditions and immunoblotted into nitrocellulose mem-
brane. The following antibodies (Abs) were used: anti-HIF-
1a rabbit (Bethyl Laboratories, Montgomery, USA); anti-
phospho-aurora A (Thr288) (CD39D8) (Cell Signaling
Technology, Boston, MA, USA); anti-VEGF (147); anti-
ARK1(N-20); and anti-GAPDH(6C5) (Santa Cruz Bio-
technology, Santa Cruz, CA, USA).
RNA interference and stabilization of HIF-1a
The small-interfering RNA (siRNA) oligonucleotides spe-
cific for human HIF-1a were purchased from Thermo
Scientific Dharmacon (ON-TARGETplus SMARTpool
L-004018-00-0005, Human HIF1A, NM_181054, 5 nmol).
ON-TARGETplus SMARTpool siRNA is a mixture of 4
siRNAs (provided as a single reagent) that target the fol-
lowing HIF-1a sequences: GAACAAAUACAUGGGA
UUA, AGAAUGAAGUGUACCCUAA, GAUGGAAGCA
CUAGACAAA, and CAAGUAGCCUCUUUGACAA. The
cells were cultured in six-well culture dishes, maintained in
2 mL of DMEM medium, and transfected by adding 5 lM
siRNA (siHIF-1a) and DharmaFECT four according to
manufacturer’s instructions. After 24–48 h (for mRNA
analysis) or 48–96 h (for protein analysis) of incubation with
siRNA and transfection reagent, the cells were exposed to
hypoxia for 24 and 48 h. ON-TARGETplus Non-targeting
Control Pool (Thermo Scientific Dharmacon) was used as
a siRNA negative control (non-specific scrambled siRNA)
(data not shown).
Furthermore, cells were incubated in the absence or the
presence of HIF hydroxylase inhibitor, dimethyloxalyl-
glycine (DMOG) (Sigma-Aldrich, St. Louis, MO), for 24
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and 48 h, at a final concentration of 1 mM. Subsequently,
cells were lysed and protein extracts were analyzed by
Western blot.
Chromatin immunoprecipitation (ChIP)
Immunoprecipitation was performed using the ChIP Assay
Kit (Millipore, Temecula, CA) according to the manufac-
turer’s protocol. 1 9 106 cells were cultured on a 10-cm
culture dish under normoxia and hypoxia (24 and 48 h).
The cells then were treated with a solution of PBS and 1 %
formaldehyde, and incubated for 8 min at 37 C in order to
cross-link histones to DNA. Cells were collected (4 min;
4 C; 4,000 rpm) and sonicated in order to shear DNA to
lengths between 200 and 1,000 bp. Soluble chromatin was
immunoprecipitated with 5 mg of HIF-1a antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) overnight at
4 C. DNA–protein immune complexes were eluted,
reverse cross-linked, and DNA was recovered by phenol/
chloroform extraction and ethanol precipitation. The binding
of HIF-1a to the AURKA promoter region -336/-236
containing the three putative HREs (HRE-1: -336/-332;
HRE-2: -323/-319; HRE-3: -240/-236) was determined
by PCR using the following primers: forward 50-AGTC
GTTTCTGTGGTTTTCTC-30 and reverse 50-GAGATAA
AGTCCAAGGAGGTGAAC-30. Furthermore, an AURKA
promoter region without HREs was used as a control using
the following primers: forward 50-CTGTTCTATCCGGT
CTCTTCACTT-30 and reverse 50-TTGGGGATAATTAG
GCTTCTGTT-30. The PCR conditions were as follows:
5 min at 95 C; 30 s at 95 C, 30 s at 60 C, 40 s at 72 C
for 35 cycles; 7 min at 72 C.
Luciferase activity assay
Luciferase assay was performed as previously described by
Klein et al. [14] using the luciferase reporter plasmidic
construct pGL3-AURKA-Luc. Firefly luciferase reporter
plasmid containing the human AURKA promoter (from
-986 to ?15) was generated using the pGL3 basic plasmid
(Promega Italia, Milano, Italy). The human AURKA pro-
moter 50-flanking region containing three putative HREs
was amplified by PCR from genomic DNA and the cor-
responding PCR product was cloned into pGL3 vector at
the KpnI and XhoI sites. BC cells were transfected with
firefly luciferase vector (pGL3-AURKA-Luc) or with
pGL3-basic-Luc empty vector used as a negative control,
using Lipofectamine 2000 (Life Technologies). A Renilla
luciferase reporter, pRL-TK (Promega), was co-transfected
as a control for normalization. After 24 h of incubation,
cells were cultured under normoxia or hypoxia (for 24 and
48 h) and then lysed in passive lysis buffer (Promega).
Luciferase activity of cell lysates was measured using the
Dual-Luciferase Reporter Assay System Kit (Promega) and
the GloMax 96 Microplate Luminometer (Promega)
according to the manufacturer’s protocol. Normalized data
were represented as the ratio of Firefly/Renilla luciferase
activities. The shown data represent the mean ± SD from
three independent experiments, each performed in duplicate.
Results
Gene expression profiling in BC cells under hypoxia
Considering that hypoxia is a condition that during tumor
growth influences the expression of several genes involved
in proliferation and cell cycle progression, we first per-
formed a microarray analysis, using Affymetrix platform,
in order to compare differential gene expression profiles in
MCF-7, MDA-MB-231, and SKBr3 human BC cell lines in
response to hypoxic exposure for 24 and 48 h. This work
was carried out in order to evaluate the involvement of
some genes in molecular pathways related to tumor path-
ogenesis. This analysis allowed us to obtain, for each
examined BC cell line, two lists of DEGs in hypoxia at 24
and 48 h with respect to normoxia (control). In particular,
for this study, the lists were screened considering as sig-
nificant only the genes with fold change (M) [ |1| (loga-
rithm scale) and P \ 0.01. Thus, we obtained six lists of
DEGs with respect to the normoxic condition, including
after 24 h of hypoxia 4,019 genes (2,482 down-regulated
and 1,537 up-regulated) for MCF-7; 4,742 genes (3,032
down-regulated and 1,710 up-regulated) for MDA-MB-
231; and 6,970 genes (4,615 down-regulated and 2,355 up-
regulated) for SKBr3; and after 48 h of hypoxia 4,229
genes (2,362 down-regulated and 1,867 up-regulated) for
MCF-7; 4,830 genes (1,832 down-regulated and 2,998 up-
regulated) for MDA-MB-231; and 9,575 genes (6,287
down-regulated and 3,288 up-regulated) for SKBr3.
Then, six lists of genes were compared with each other
and analyzed in order to identify a set of DEGs common to
three BC cell lines (Supplementary Table S1). Using Venn
diagrams, we found 270 shared genes (81 down-regulated
and 189 up-regulated) that showed a gene expression var-
iation in hypoxia (24 and 48 h) with respect to normoxia.
Furthermore, 725 genes showed an altered expression only
in MCF-7, 511 genes in MDA-MB-231, and 2513 genes in
SKBr3 (Fig. 1).
Molecular pathways altered in hypoxia
A further series of studies was conducted on the microarray
analysis data in order to identify any genes of particular
interest. Our attention was focused mainly on the genes
involved in proliferation, cell cycle progression, mitosis,
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and response to hypoxia. The integrated analysis resulting
from KEGG and Biocarta databases allowed us to identify
the main molecular pathways altered in BC cell lines after
hypoxic exposure for 24 and 48 h. This analysis indicated
that the genes showing a significant variation in expression
levels were included in the following three pathways: cell
cycle regulation (35 genes), HIF-1a network (15 genes),
and AURKA signaling (12 genes). The DEGs involved in
these pathways were grouped in heat maps (Fig. 2). A
considerable number of genes involved in proliferation and
cell cycle control, through the G1/S and G2/M transitions,
exhibited a significantly deregulated expression in all three
BC cell lines (Fig. 2a). Among the DEGs in hypoxia,
required for G1/S transition, CDC6, CCND1, CCNE2, and
CDK2 were tendentially down-regulated, whereas
CDKN1A (p21Cip1) was up-regulated. Instead, CDC25A
was down-regulated in MCF-7 and SKBr3 cells and up-
regulated in MDA-MB-231 cells. Moreover, we found that
in MCF-7 and SKBr3 cells, hypoxia induces down-regu-
lation of several genes required for G2/M transition, such
as CCNA2, CCNB1, CCNB2, CDC2 (CDK1), and CDC25C.
The same results were shown by MDA-MB-231 cells under
hypoxic conditions for 24 h (Supplementary Table S2).
In addition, significant increases in expression levels
were also observed in key genes involved in HIF-1a net-
work (Fig. 2b), such as VEGF-A, SLC2A1, JUN, FOS, and
other genes encoding for glycolytic enzymes (PGK1,
PFKFB3, HK2, ALDOA) (Supplementary Table S3).
Finally, microarray analysis showed a significant variation
in expression levels of some genes that regulate the mitosis
included in AURKA signaling pathway (Fig. 2c). This
analysis revealed that hypoxia induces a noteworthy down-
regulation of AURKA expression. Other genes involved in
the same pathway, such as AURKB, JUB (ajuba), and
TPX2, were tendentially down-regulated in all three BC
cell lines under hypoxic conditions (Supplementary
Table S4).
AURKA down-regulation in BC cells under hypoxia
In particular, our analyses were focused mainly on effects of
hypoxia on AURKA expression and molecular mechanisms
that regulate this. As previously described, in all three
examined BC cell lines, in response to hypoxia, a down-
regulation of AURKA expression compared to normoxia (fold
changes: -2.19 and -3.55 in MCF-7; -2.56 and -1.51 in
MDA-MB-231; and -1.84 and -3.17 in SKBr3, at 24
and 48 h, respectively) and a concomitant decrease in
expression levels of JUB (fold changes: -1.90 and -2.60 in
MCF-7; -3.43 and -1.78 in MDA-MB-231; and -1.14 and
-1.65 in SKBr3, at 24 and 48 h, respectively) were observed.
Both TPX2 and AURKB also showed a parallel down-regu-
lation of their expression in hypoxia, except that in MDA-
MB-231 cells exposed to hypoxia for 48 h (fold change:
?1.22 and ?1.20, respectively). Furthermore, microarray
analysis revealed, following hypoxic exposure, significant
changes in expression levels of AURKA-related genes that
regulate the G2/M transition and mitosis, such as CCNB1,
CCNB2, CDC2, CDC25B, and TACC1. All these genes
exhibited a negative fold change (M), except CCNB2
(M = ?1.73) and CDC2 (M = ?1.19) in MDA-MB-231
cells, after hypoxia for 48 h (Table 1). In order to validate
microarray analysis data, we evaluated the AURKA mRNA
expression levels in the same BC cell lines under hypoxic
conditions, using qRT-PCR and RT-PCR (Fig. 3a, b). The
qRT-PCR analysis confirmed that hypoxia induces a AURKA
down-regulation, with an increased reduction of mRNA
expression levels after 48 h of exposure in MCF-7 and SKBr3
cells (0.15-fold and 0.2-fold, respectively), and with an initial
decrease after 24 h (0.25-fold) followed by a partial expres-
sion increase after 48 h (0.45-fold) in MDA-MB-231 cells
(Fig. 3a). Similar results were obtained by means of RT-PCR
analysis (Fig. 3b). Interestingly, in parallel to AURKA mRNA
down-regulation, we observed, through Western blot (WB)
analysis, a reduction of AURKA protein levels in MCF-7 and
SKBr3 cells after 24 and 48 h of hypoxia, compared to the
control condition (normoxia). Differently, as demonstrated by
microarray analysis, MDA-MB-231 cells showed a reduction
in AURKA protein levels after 24 h, with a partial increase in
Fig. 1 Venn diagrams summarizing DEGs in breast cancer cell lines
in response to hypoxia. The number of total, unique, and common
DEGs (M [ |1| and P \ 0.01) is shown. Each Venn diagram includes
for each cell line the number of genes (down- and up-regulated)
whose expression is altered in hypoxic conditions (for 24 and 48 h)
with respect to normoxia: 1,785 genes for MCF-7; 1,313 genes for
MDA-MB-231; and 3,977 genes for SKBr3. The intersection among
three Venn diagrams has allowed the identification of 270 DEGs
shared by all three cell lines in response to hypoxia
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the expression after 48 h of exposure to hypoxia. Consistent
with our findings, together with a reduction of the AURKA
protein expression, we detected a decrease in expression
levels of phospho-aurora A (Thr288) and an increase in HIF-
1a and VEGF-A protein levels in BC cells under hypoxia.
However, HIF-1a showed a lower expression level in MDA-
MB-231 cells exposed to hypoxia for 48 h (Fig. 3c).
Hypoxia down-regulates AURKA expression in a HIF-
1a-dependent manner
Since HIF-1a is a key transcription factor during hypoxia,
we investigated its role in down-regulation of AURKA
expression in BC cells exposed to hypoxia. To determine
whether AURKA down-regulation was due to the expression
of HIF-1a, we evaluated AURKA expression variations in
HIF-1a-silenced cells. Therefore, HIF-1a-dependent effects
of hypoxia were reversed by silencing HIF-1a mRNA
expression with a specific siRNA pool targeting HIF-1a
(siHIF-1a). A non-targeting control pool was used as a
siRNA negative control (data not shown). Using qRT-PCR
analysis, specific knockdown of HIF-1a was confirmed at
the mRNA level and a significant increase in AURKA
mRNA expression levels was observed in all three analyzed
BC cell lines, following HIF-1a silencing (Fig. 4a). In
MCF-7 and SKBr3 cells, knockdown of HIF-1a induced a
greater increase of AURKA expression after 48 h of hypoxia
(from 0.15-fold to 0.75-fold and from 0.2-fold to 0.7-fold,
respectively) in comparison to that found after 24 h (from
0.45-fold to 0.65-fold and from 0.3-fold to 0.6-fold,
respectively). In MDA-MB-231 cells, a lower increase was
observed after 48 h of hypoxia (from 0.6-fold to 0.7-fold)
with respect to that detected after 24 h (from 0.3-fold to 0.6-
fold) (Fig. 4a). Similar results, after HIF-1a silencing, were
obtained by means of RT-PCR analysis (Fig. 4b). Specific
knockdown of HIF-1a was also evaluated at the protein
level. WB analysis showed a good correlation with data
previously obtained. In BC cells, silencing of HIF-1a by
RNA interference induced a significant increase in AURKA
and phospho-aurora A (p-AURKA) protein levels after 24
and 48 h of hypoxia. Greater differences in protein expres-
sion were detected in hypoxic condition at 48 h, except that
Fig. 2 Heat maps of common DEGs involved in main molecular
pathways deregulated in hypoxia. Clustering of common DEGs
involved in a cell cycle regulation pathway, b HIF-1a network, and
c AURKA signaling pathway. The heat maps were generated from
microarray data reflecting gene expression values in MCF-7, MDA-
MB-231, and SKBr3 cells exposed to hypoxia (3 % O2) for 24 and
48 h in comparison to control cells cultured under normoxic
conditions (M [ |1| and P \ 0.01). Each row represents the expres-
sion levels for a single gene tested for different experimental
conditions. Each column shows the expression levels for the genes
tested for a single experimental condition. The absolute expression
value (log scale) of each gene is derived from the mean of two
biological replicates. The color scale bar on the top represents signal
intensity variations ranging from green (poorly expressed genes) to
red (highly expressed genes). Black boxes indicate intermediate
expression values. N normoxia; H24 hypoxia for 24 h; H48 hypoxia
for 48 h
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in MDA-MB-231 cells. Furthermore, in all three BC cell
lines, WB analysis showed a substantial hypoxia-mediated
up-regulation of VEGF-A in the absence of siHIF-1a and a
considerable reduction in protein expression levels in cells
transfected with siHIF-1a (Fig. 4c).
At the same time, in order to further assess the HIF-1
potential role in regulation of hypoxia-mediated AURKA
expression, BC cells were treated with DMOG, a cell-per-
meable inhibitor of both proline and asparaginyl
hydroxylases able to induce HIF-1a stabilization in nor-
moxia. Thus, treatment of MCF-7, MDA-MB-231, and
SKBr3 cells with a PHD inhibitor (for 24 and 48 h) caused
the activation of the HIF-1 pathway in normoxia. In fact,
WB analysis provided results comparable to those previ-
ously described, leading to an increase in HIF-1a expression
levels and concomitant reduction of AURKA expression in
the presence of DMOG. Interestingly, in MDA-MB-231
cells, a lower HIF-1a induction was observed after 48 h of
Table 1 Effects of hypoxia on expression of genes related to AURKA
ID Affymetrix Gene symbol MCF-7 MDA-MB-231 SKBr3
MH24 MH48 MH24 MH48 MH24 MH48
208079_s_at AURKA -2.19 -3.55 -2.56 -1.51 -1.84 -3.17
209464_at AURKB -1.76 -1.46 -1.14 ?1.20 -1.06 -2.24
228729_at CCNB1 -1.46 -2.15 -2.47 -1.15 -2.65 -4.65
202705_at CCNB2 -1.91 -2.16 -1.38 ?1.73 -2.51 -3.49
203213_at CDC2 -2.00 -1.88 -1.12 ?1.19 -1.52 -3.74
201853_s_at CDC25B -1.97 -1.42 -1.87 -1.31 -1.93 -3.27
225806_at JUB -1.90 -2.60 -3.43 -1.78 -1.14 -1.65
200911_s_at TACC1 -2.18 -2.36 -2.19 -1.13 -1.73 -1.07
210052_s_at TPX2 -1.73 -2.39 -1.22 ?1.22 -1.07 -2.73
MH24 represents the fold change of hypoxia versus normoxia (control) at 24 h. MH48 represents the fold change of hypoxia versus normoxia at
48 h. All showed fold change (M) values are in logarithm scale. M [ |1| and P \ 0.01
Fig. 3 Effects of hypoxia on AURKA expression in breast cancer
cell lines. a Validation of microarray data by quantitative real-time
PCR analysis. Changes in AURKA mRNA expression levels were
determined in MCF-7, MDA-MB-231, and SKBr3 cells exposed to
hypoxia (3 % O2) for 24 and 48 h with respect to control condition
(normoxia, 16 % O2). Relative transcript levels were determined
using the 2-DDCt method and normalized to b-actin mRNA (endog-
enous control). Normoxic condition values are taken as 1 and hypoxic
condition values represent fold decrease relative to control condition.
Data are presented as fold changes ±SDs. Significant difference,
hypoxia for 24 h (H24) or for 48 h (H48) versus normoxia (N),
*P \ 0.05. b Quantification of AURKA mRNA expression using RT-
PCR analysis. c Effects of hypoxia on VEGF, AURKA, p-AURKA,
and HIF-1a protein expression levels in MCF-7, MDA-MB-231, and
SKBr3 cells. Protein expression was examined by Western Blot
analysis with the indicated antibodies, by developing with the
enhanced chemiluminescence reagent (ECL). p-AURKA represents
phospho-aurora A (Thr288). The GAPDH house-keeping protein was
used as loading control. The experiments were performed at least
three different times and the results were always similar. N normoxia;
H24 hypoxia for 24 h; H48 hypoxia for 48 h
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incubation with DMOG with respect to treatment for 24 h,
and a partial recovery of AURKA expression was detected
(Fig. 5).
According to these results, we suggest that HIF-1 could act
directly or indirectly as a possible negative regulator of AU-
RKA expression in BC cell lines cultured in hypoxic conditions.
Fig. 4 Effects of HIF-1a silencing on AURKA expression in breast
cancer cells under hypoxic conditions. MCF-7, MDA-MB-231, and
SKBr3 cells were transfected with a siRNA pool targeting HIF-1a
(siHIF-1a) and subsequently exposed to hypoxia (3 % O2) for 24 and
48 h. For all experiments, a non-targeting control pool was used as a
siRNA negative control (data not shown). a Specific knockdown of HIF-
1a was confirmed at the mRNA level using qRT-PCR analysis.
Variations in AURKA and HIF-1a mRNA expression levels with respect
to control condition (normoxia, 16 % O2) were evaluated in breast
cancer cells with and without siHIF-1a. Relative transcript levels were
determined using the 2-DDCt method and normalized to b-actin mRNA
(endogenous control). Data are presented as fold changes ±SDs. AURKA
mRNA expression values are in linear scale, while those of HIF-1a are in
logarithm scale. Significant differences: hypoxia for 24 h (H24) or for
48 h (H48) versus normoxia (N), *P \ 0.05; H24? siHIF-1a versus
H24, or H48? siHIF-1a versus H48, **P \ 0.05. b Quantification of
AURKA mRNA expression after HIF-1a silencing using RT-PCR
analysis. c Effects of HIF-1a silencing on VEGF, AURKA, p-AURKA,
and HIF-1a protein expression levels in breast cancer cells transfected
(?) or not (-) with siHIF-1a. Specific knockdown of HIF-1a was
assessed at the protein level by Western Blot analysis. p-AURKA
represents phospho-aurora A (Thr288). The GAPDH protein was used as
a loading control. The experiments were performed at least three
different times and the results were always similar
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Involvement of HIF-1a in transcriptional regulation
of AURKA
Since previously obtained results suggest that HIF-1a
could mediate AURKA down-regulation in BC cells under
hypoxia, we aimed to obtain new insights into the regula-
tion of AURKA expression. Therefore, we investigated the
role of HIF-1 as hypothetical transcriptional repressor of
the AURKA promoter. HIF-1 regulates the transcription of
its target genes usually via binding to HREs. Sequence
analysis identified three putative HREs sites into AURKA
proximal promoter (HRE-1: -336/-332; HRE-2: -323/
-319; and HRE-3: -240/-236) [14]. Thus, a ChIP assay
was performed using an antibody against HIF-1a in BC
cells exposed to hypoxia, in order to evaluate the effects of
hypoxia on HIF-1a binding to the HREs into the proximal
region of AURKA promoter. Then, quantitative PCR anal-
ysis, performed with specific primers for the AURKA pro-
moter fragment containing the three HREs, revealed that
HIF-1a binds to the AURKA promoter. This analysis
showed that HIF-1a does not bind AURKA promoter in
MCF-7, MDA-MB-231, and SKBr3 cells under normoxia.
However, this binding was enhanced after hypoxic expo-
sure for 24 and 48 h in MCF-7 and SKBr3 cells and
maximal binding was observed after 48 h of hypoxia.
Differently, increased binding was detected in MDA-MB-
231 cells after 24 h of hypoxia followed by an evident
reduction after 48 h (Fig. 6). The reduced HIF-1a binding
to AURKA promoter region, observed after 48 h of hypoxia
in MDA-MB-231 cells, supports our hypothesis because, in
response to a decreased binding, we found an increase in
mRNA and protein levels of AURKA and p-AURKA.
These results nicely correlate with those previously
obtained from gene and protein expression analyses.
Also, in order to further investigate whether hypoxia
was involved in regulation of AURKA promoter activity,
we performed a luciferase reporter assay. For this purpose,
an AURKA promoter fragment containing three putative
HREs was cloned into pGL3 vector at the sites between
KpnI and XhoI giving the pGL3-AURKA-Luc plasmidic
construct. BC cells were transfected with this construct and
luciferase activity was measured after incubation under
normoxia and hypoxia. We found that luciferase activity
was significantly decreased in MCF-7, MDA-MB-231, and
SKBr3 cells transfected with pGL3-AURKA-Luc and
incubated in hypoxia (for 24 and 48 h) compared to cells
transfected with empty vector (pGL3-basic-Luc), suggest-
ing a hypoxia-mediated reduction of AURKA promoter
activity (Fig. 7a).
Fig. 5 Effects of HIF-1a stabilization on AURKA expression. MCF-
7, MDA-MB-231, and SKBr3 cells were incubated in the absence (-)
or the presence (?) of 1 mM DMOG for 24 h (H24) and 48 h (H48)
in normoxic conditions. Cells were lysed and protein extracts were
analyzed by Western Blot analysis, in order to assess HIF-1a
stabilization and AURKA expression levels. GAPDH protein was
used as a loading control
Fig. 6 Effects of hypoxia on HIF-1a binding to proximal region
of AURKA promoter. The binding of HIF-1a to the proximal region
(-336/-236) of AURKA promoter was tested by ChIP assay (as
described in ‘‘Methods’’ section) using an antibody against HIF-1a in
MCF-7, MDA-MB-231, and SKBr3 breast cancer cells cultured in
normoxic (16 % O2) and hypoxic (3 % O2, for 24 and 48 h)
conditions. Interaction between HIF-1a and AURKA promoter region
containing HRE-1, HRE-2, and HRE-3 (AURKA ? HREs) was
analyzed by q-PCR. An AURKA promoter region containing no HREs
was used as a control (AURKA-HREs). N normoxia; H24 hypoxia
for 24 h; H48 hypoxia for 48 h
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Furthermore, to evaluate the possible HIF-1 role in reg-
ulation of AURKA promoter activity, a specific siRNA pool
targeting HIF-1a (siHIF-1a) was co-transfected with pGL3-
AURKA-Luc plasmid in BC cells and a siRNA scramble
was used as a negative control. After co-transfection, cells
were incubated under normoxia and hypoxia, and luciferase
activity was determined. We observed that cells transfected
with siHIF-1a showed an increase of luciferase activity
compared to cells transfected with negative control
(scramble), indicating a higher induction of AURKA pro-
moter activity after HIF-1a knockdown. In particular, HIF-
1a-silenced MCF-7 and SKBr3 cells showed a higher
increase of AURKA promoter activity after 48 h of hypoxia
(Fig. 7b). Therefore, these data suggest that HIF-1a could be
involved in the negative regulation of AURKA expression,
indicating a new possible transcriptional role of HIF-1 in BC
cell lines.
Discussion
Nowadays, although oncologists have several available
options (chemotherapy, hormone therapy, and biologic
agents such as anti-angiogenic and anti-HER2 drugs), BC
is still responsible for a significant percentage of cancer
deaths in women [43, 44].
Hypoxia is a typical feature of the microenvironment of
several solid tumors and is associated with poor prognosis
in several cancer types, including BC [45]. Since tumor
hypoxia is known to be an important factor for the
expression of many genes involved in tumorigenesis and
cell cycle regulation [46], we performed a microarray-
based gene expression analysis in order to determine dif-
ferent expression profiles in MCF-7, MDA-MB-231, and
SKBr3 BC cells in response to hypoxia for 24 and 48 h.
This study allowed us to identify a set of 270 DEGs in
hypoxia common to three BC cell lines. Our attention was
focused mainly on the genes showing a significant varia-
tion in expression levels involved in proliferation, cell
cycle progression and regulation, mitosis, and response to
hypoxia. Three main molecular pathways were found
altered in BC cell lines after hypoxia for 24 and 48 h: cell
cycle regulation, HIF-1a network, and AURKA signaling.
Among the DEGs involved in proliferation and cell cycle
control, CDKN1A (p21Cip1), that can elicit the G1/S
checkpoint, was up-regulated, while genes that further
determine entry from G1 to S-phase, including CDC6,
CCND1, CCNE2, and CDK2, were tendentially decreased
in expression. Furthermore, CDC25A was down-regulated
in MCF-7 and SKBr3 cells and up-regulated in MDA-MB-
231 cells. Concomitant with decreased G1 to S-phase
progression, a reduced expression of genes that regulate the
passage of cells through G2/M, such as CCNA2, CCNB1,
CCNB2, CDC2 (CDK1), and CDC25C, was also demon-
strated in MCF-7 and SKBr3 cells exposed to hypoxia for
24 and 48 h, and in MDA-MB-231 cells under hypoxia for
24 h. In addition, among the DEGs involved in HIF-1a
network, VEGF-A, SLC2A1, JUN, FOS, and other genes
Fig. 7 Regulation of AURKA promoter activity under hypoxia.
Transcriptional activity of AURKA promoter under hypoxia was
evaluated by luciferase assay using the following plasmidic vectors:
pGL3-AURKA-Luc, pGL3-basic-Luc (negative control), and pRL-
TK. Firefly luciferase activity was normalized to Renilla luciferase
activity. Luciferase activity of cell lysates was determined by the
Dual-Luciferase Reporter Assay System (Promega). Data represent
mean ± SD from triplicate sets. Normalized luciferase activity in the
respective controls was set to 1. a Breast cancer cells were co-
transfected with the pGL3-AURKA-Luc firefly luciferase vector and
pRL-TK Renilla luciferase vector or with the pGL3-basic-Luc empty
vector and, after 24 h, incubated under normoxia or hypoxia (for 24
and 48 h). Significant difference, hypoxia for 24 h (H24) or for 48 h
(H48) versus normoxia (N), *P \ 0.05. b Cells were co-transfected
with the pGL3-AURKA-Luc construct and a specific siRNA pool
targeting HIF-1a (siHIF-1a) as well as pRL-TK vector and, after
24 h, incubated under normoxia or hypoxia (for 24 and 48 h). A non-
targeting control pool (scramble) was co-transfected as a siRNA
negative control. *Significant difference, H24 or H48 versus N in
each experimental condition and **significant difference, H24 pGL3-
AURKA-Luc ? siHIF-1a versus H24 pGL3-AURKA-Luc ? scram-
ble and H48 pGL3-AURKA-Luc ? siHIF-1a versus H48 pGL3-
AURKA-Luc ? scramble, P \ 0.05
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encoding for glycolytic enzymes (PGK1, PFKFB3, HK2,
ALDOA) were up-regulated in all three analyzed BC cell
lines. Finally, genes that regulate the mitosis included in
AURKA signaling pathway, such as AURKA, AURKB,
JUB (ajuba), and TPX2, showed a significant down-regu-
lation in expression levels. These changes could be
responsible for genomic instability in BC. For the first
time, our study showed that hypoxia induces a noteworthy
down-regulation of AURKA expression in BC cell lines.
The Aurora family kinases, especially aurora-A, play a
particularly important role in the cell cycle and their
deregulated expression is involved in many types of human
malignancies [47, 48]. Several studies showed that aurora-
A overexpression correlates with tumorigenesis, metasta-
sis, and chemoresistance, confirming its pro-survival
function in cancer cells [49–51]. Although in the literature
there is evidence describing the activation of AURKA in
different tumors, the mechanism of transcriptional up-
regulation of AURKA in human BC is not yet elucidated
[15]. Thus, the understanding of the regulatory pathways
that mediate a reduced transcription of AURKA could be
important, in order to identify new possible mechanisms
counteracting not only BC progression but also the devel-
opment of other tumors associated with AURKA overex-
pression. Therefore, our work focused mainly on effects of
hypoxia on AURKA expression in BC cells and molecular
mechanisms that regulate this. MCF-7, MDA-MB-231, and
SKBr3 cells, in response to hypoxia for 24 and 48 h,
showed a down-regulation of AURKA expression compared
to normoxic condition, with a partial increase of expression
after 48 h only in MDA-MB-231 cells. Moreover, micro-
array analysis revealed a parallel decrease in expression
levels of AURKB and two AURKA co-activators, JUB and
TPX2. However, according to the recovery of AURKA
expression, AURKB and TPX2 exhibited positive fold
change in MDA-MB-231 cells exposed to hypoxia for
48 h, and JUB showed a partial increase of expression with
respect to hypoxic condition at 24 h. Further analyses at
protein level confirmed that hypoxia induces a decreased
expression of AURKA, with an increased reduction of
expression levels after 48 h of exposure to hypoxia in
MCF-7 and SKBr3 cells, and with an initial decrease after
24 h followed by a partial recovery of expression after 48 h
in MDA-MB-231 cells. Together with the reduction of the
AURKA protein expression, an increase in HIF-1a and
VEGF-A protein levels was observed. However, HIF-1a
showed a lower expression level in MDA-MB-231 cells
exposed to hypoxia for 48 h. From these data, HIF-1a
expression seems to be inversely related to AURKA
expression.
Since HIF-1a plays a pivotal role in the homeostatic
mechanisms involved in the cellular response to hypoxic
stress, we investigated its role in AURKA down-regulation
in BC cells exposed to hypoxia. To determine whether
AURKA down-regulation was caused by increased
expression of HIF-1a in hypoxia, variations in AURKA
expression were evaluated, both at mRNA and protein
level, in BC cells transfected with a specific siRNA pool
targeting HIF-1a (siHIF-1a). Thus, HIF-1a-dependent
effects of hypoxic exposure were reversed by siRNA-
mediated silencing of HIF-1a. Our data suggest that HIF-
1a could be involved in the regulation of AURKA
expression in hypoxia because expression of siRNA against
HIF-1a reduced the down-regulation of AURKA in BC cell
lines. In MCF-7 and SKBr3 cells, specific knockdown of
HIF-1a induced a greater difference of AURKA expression
in hypoxia at 48 h in comparison to that detected at 24 h.
In MDA-MB-231 cells, a lower difference was observed at
48 h with respect to that found at 24 h. At the same time,
cells were treated with DMOG that induces an increase in
HIF-1a expression levels in normoxia, by inhibiting the
PHDs. A lower AURKA expression was found in corre-
spondence to higher HIF-1a expression levels. These
findings suggest that hypoxia could down-regulate AURKA
expression in a HIF-1a-dependent manner in BC cell lines.
Since the molecular mechanisms through which AURKA is
regulated in response to hypoxic condition are unknown in
BC, the overall goal of this investigation was to obtain new
insights on the regulation of AURKA expression in BC cells
cultured under normoxia and hypoxia, by evaluating the
possible HIF-1 role in transcriptional control of AURKA
expression. HIF-1 regulates the transcription of its target
genes usually via binding to HREs. Three putative HREs
sites were identified into AURKA proximal promoter. In
hepatocellular carcinoma, the stabilization of HIF-1a not
only induces the expression of genes involved in angio-
genesis, glucidic metabolism, and survival but also causes
AURKA up-regulation via its hypoxia-dependent binding to
the HREs [14]. Moreover, in 2010, Xu et al. [52] reported
that VHL inactivation stabilizes HIF-1a inducing AURKA
up-regulation in clear cell renal cell carcinoma (CCRCC)
cell lines. Unlike the previous findings, we hypothesize a
new possible mechanism where HIF-1 rather than inducing
transcriptional activation could promote the AURKA down-
regulation via its binding to HREs into proximal region of
AURKA promoter in BC cells under hypoxia. Therefore,
we investigated the potential role of HIF-1 as hypothetical
transcriptional repressor of the AURKA promoter in the
three BC cell lines. Our study showed that HIF-1a does not
bind to the AURKA promoter region containing three HREs
in BC cells under normoxia, but its binding is enhanced
after hypoxic exposure for 24 and 48 h in MCF-7 and
SKBr3 cells, and a maximal binding is observed after 48 h
of hypoxia. Differently, MDA-MB-231 cells showed an
increased binding after 24 h of hypoxia followed by an
evident reduction after 48 h. Our analyses indicated that
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MDA-MB-231 cells show a different behavior concerning
the AURKA expression after 48 h of hypoxia with respect
to MCF-7 and SKBr3 cells. This could be attributed to a
different expression level of HIF-1a that binds to a lesser
extent the AURKA promoter. Therefore, in support of our
hypothesis, the increased HIF-1a binding into the proximal
region of AURKA promoter is related to a decrease in gene
and protein expression levels of AURKA. Furthermore, to
investigate whether HIF-1 regulates AURKA expression in
hypoxia, luciferase assays were performed, showing a
partial recovery of AURKA promoter activity after HIF-1a
knockdown. Therefore, these results suggest a new possible
transcriptional role of HIF-1 that could determine a nega-
tive control of AURKA expression in BC cell lines under
hypoxia. If HIF-1 acts directly as a possible transcriptional
repressor of AURKA inhibiting the binding of RNA Poly-
merase II to its own site, or indirectly, preventing the
binding of a transcriptional activator is yet unknown. This
will be the subject of our future research as well as for a
better understanding of the molecular bases of this down-
regulation, by evaluating whether HIF-1 alone is directly
involved in transcriptional control of AURKA in hypoxia or
if other co-repressor proteins are implicated.
For the first time, the present study shows that hypoxia
directly links HIF-1 with AURKA expression in BC,
highlighting a possible pathophysiological role of this new
pathway in this tumor and confirming HIF-1 as an impor-
tant player linking an environmental signal to the AURKA
promoter. Since AURKA is a key regulator of the chro-
mosomal segregation process in mammalian cells and its
down-regulation overrides the estrogen-mediated growth
and chemoresistance in BC cells [53], these results could
provide innovative approaches for the development of
novel possible therapeutic strategies against BC.
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